GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Cost of Goods Sold

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Cost of Goods Sold : $0.01 Mil (TTM As of Feb. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Cost of Goods Sold?

CNBX Pharmaceuticals's cost of goods sold for the three months ended in Feb. 2024 was $0.01 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Feb. 2024 was $0.01 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CNBX Pharmaceuticals's Gross Margin % for the three months ended in Feb. 2024 was 82.93%.

Cost of Goods Sold is also directly linked to Inventory Turnover.


CNBX Pharmaceuticals Cost of Goods Sold Historical Data

The historical data trend for CNBX Pharmaceuticals's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Cost of Goods Sold Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.01

CNBX Pharmaceuticals Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals  (OTCPK:CNBX) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CNBX Pharmaceuticals's Gross Margin % for the three months ended in Feb. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(0.041 - 0.007) / 0.041
=82.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

CNBX Pharmaceuticals's Inventory Turnover for the three months ended in Feb. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


CNBX Pharmaceuticals Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary